“One pill, once daily”: what clinicians need to know about Atripla™

References

• AbramowiczMA once-daily combination tablet (Atripla) for HIVMed Letter2006a487880
   Google Scholar
• AbramowiczMTreatment guidelines from the Medical Letter: Drugs for HIV infectionMed Letter2006b506776
   Google Scholar
• AmmassariATrottaMPMurriRAdICoNA Study GroupCorrelates and predictors of adherence to highly active antiretroviral therapy: overview of published literatureJ Acquir Immun Defic Syndr200231Suppl 3S1237
   PubMed Web of Science ®Google Scholar
• ArribasJRPozniakALGallantJETenofovir disoproxil fumarate, emtricitabine and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysisJ Acquir Immune Defic Syndr2007a1025 Epub ahead of print
   PubMed Web of Science ®Google Scholar
• ArribasJPozniakAGallantJThree-year safety and efficacy of emtricitabine (FTC)/tenofovir DF (TDF) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral treatment-naive patients2007bProgram and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and PreventionJuly, 22–25, 2007Sydney, Australia Abstract WEPEB029
   Google Scholar
• Atripla™ Package InsertBristol-MyersSquibb and Gilead Sciences2006Foster City, California, USLLC July 2006
   Google Scholar
• BadriSMAdeyemiOMMaxBEUtility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failureAIDS Patient Care STDS2007215445017711379
   PubMed Web of Science ®Google Scholar
• BarrettJSJoshiASChaiMPopulation pharmacokinetic meta-analysis with efavirenzInt J Clin Pharmacol Ther2002405071912698988
   PubMed Web of Science ®Google Scholar
• BartlettJAFathMJDemasiRAn updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adultsAIDS20062020516417053351
   PubMed Web of Science ®Google Scholar
• BartlettJGLaneCLUS DHHS guidelines for the use of antiretroviral agents in HIV-1 adults and adolescents2007 Accessed August 10, 2007. URL: http://aidsinfo.nih.gov
   Google Scholar
• BlowerSSmithROkanoJEvolving waves of single, dual and triple class resistance in San Francisco20072007 HIV Resistance WorkshopJune 12–16, 2007Barbados, West Indies Abstract # 38
   Google Scholar
• BroderSGalloRCA pathogenic retrovirus (HTLV-III) linked to AIDSN Eng J Med198431112927
   PubMed Web of Science ®Google Scholar
• [CDC] Centers for Disease Control and PreventionHIV/AIDS Surveillance Report200517Rev edAtlantaU.S. Department of Health and Human Services, Centers for Disease Control and Prevention154 URL: http://cdc.gov/hiv/topics/surveillance/resources/reports/
   Google Scholar
• ChanDCKimPSHIV entry and its inhibitionCell19989368149630213
   PubMed Web of Science ®Google Scholar
• ChanderGHimelhochSMooreRDSubstance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapyDrugs2006667698916706551
   PubMed Web of Science ®Google Scholar
• ChapmanTMcGavinJNobleSTenofovir disoproxil fumarateDrugs200363159760812887265
   PubMed Web of Science ®Google Scholar
• CharpentierCNoraTTenallionOExtensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patientsJ Virol20068024728216474154
   PubMed Web of Science ®Google Scholar
• ChunTWCarruthLFinziDQuantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature199738718389144289
   PubMed Web of Science ®Google Scholar
• ChunTWFinziDMargolickJIn vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latencyNat Med199511284907489410
   PubMed Web of Science ®Google Scholar
• CoombsRWCollierACAllainJPPlasma viremia in human immunodeficiency virus infectionN Engl J Med19893211626312511447
   PubMed Web of Science ®Google Scholar
• CsajkaCMarzoliniCFattingerKPopulation pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infectionClin Pharmacol Ther200373203012545140
   PubMed Web of Science ®Google Scholar
• DandoTMWagstaffAJEmtricitabine/tenofovir disoproxil fumarateDrugs20046420758215341498
   PubMed Web of Science ®Google Scholar
• EggerMMayMCheneGPrognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studiesLancet20023601192912126821
   PubMed Web of Science ®Google Scholar
• Emtriva® Package InsertOnce-daily versus twice-daily lopinavir/ritonavir in antiretroviral naïve HIV-positive patients: a 48-week randomized clinical trialJ Infec Dis2006Foster City, CaliforniaGilead Sciences, Inc. December 2006
   Google Scholar
• EnejosaJChenSSChengMKEfficacy and safety of tenofovir DF (TDF) containing versus thymidine analog-containing regimens in antiretroviral naïve HIV-1 infected women2006HIV DART 2006: Frontiers in Drug Development for Antiretroviral TherapiesDecember 10–14, 2006Cancun, Mexico
   Google Scholar
• EronJJFeinbergJKesslerHA200418926572
   Google Scholar
• FinziDBlanksonJSilicianoJDLatent infection of CD4+ T-cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective therapyNature Med19995512710229227
   PubMed Web of Science ®Google Scholar
• FlemingTRed Book 2007: Pharmacy’s Fundamental Reference2007Tampa, FLThomson Publishing Group
   Google Scholar
• FolksTKellyJBennSSusceptibility of normal human lymphocytes to infection with HTLV-III/LAVJ Immunol19861364049532422271
   PubMed Web of Science ®Google Scholar
• FramptonJECroomKFEfavirenz/emtricitabine/tenofovir disoproxil fumarate triple combination tabletDrugs20066615011216906786
   PubMed Web of Science ®Google Scholar
• FramptonJEPerryCMEmtricitabine: a review of its use in the management of HIV infectionDrugs20056514274815977972
   PubMed Web of Science ®Google Scholar
• GallantJEDeJesusEArribasJRTenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIVN Engl J Med20063542516016421366
   PubMed Web of Science ®Google Scholar
• Garcia-BlancoMACullenBRMolecular basis of latency in pathogenic human virusesScience1991254815201658933
   PubMed Web of Science ®Google Scholar
• GatanagaHHayashidaTTsuchiyaKSuccessful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26Clin Infect Dis2007451230717918089
   PubMed Web of Science ®Google Scholar
• GlarosAGGlassEGGatchelRJBlanchardEBTemporomandibular disordersPsychophysiological disorders: Research and clinical applications1993Washington, DCAmerican Psychological Association299356
   Google Scholar
• GoedkenAMHermanRAOnce daily abacavir in place of twice-daily administrationAnn Pharmacother2005391302815956231
   PubMed Web of Science ®Google Scholar
• GulickRMMellorsJWHavlirDTreatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapyN Eng J Med19973377349
   PubMed Web of Science ®Google Scholar
• HaasDWRibaudoHJKimRBPharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trial group studyAIDS200418239140015622315
   PubMed Web of Science ®Google Scholar
• HammerSMSaagMSSchechterMTreatment for HIV infection: 2006 recommendations of the International AIDS Society - USA PanelJ Amer Med Assoc200629682743
   PubMed Web of Science ®Google Scholar
• HammerSMSquiresKEHughesMDA controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study TeamN Eng J Med199733772533
   PubMed Web of Science ®Google Scholar
• HaynesRBTaylorDWSackettDLCompliance in health care1979BaltimoreJohns Hopkins University Press
   Google Scholar
• HeeswijkRPVeldkampAIMulderJWThe steady-state pharmacokinetics of nevirapine during once and twice daily dosing in HIV-1 infected individualsAIDS2000147782
   Web of Science ®Google Scholar
• HoDDMoudgilTAlamMQuantitation of human immunodeficiency virus type-1 in the blood of infected personsN Engl J Med1989321162152586564
   PubMed Web of Science ®Google Scholar
• IzzedineHIsnard-BagnisCHulotJRenal safety of tenofovir in HIV treatment-experienced patientsAIDS2004181006778
   Web of Science ®Google Scholar
• IzzedineHHulotJVittecoqDLong-term renal safety of tenofovir disoproxil fumarate in antiretroviral naive HIV-1 infected patients. Data from a double-blind randomized active-controlled mutlicentre studyNephrol Dial Transplant2005743615741212
   PubMed Web of Science ®Google Scholar
• JohnsonVABrun-VezinetFClotetBUpdate of the drug resistance mutations HIV-1: 2007Top HIV Med2007151192517720996
   PubMedGoogle Scholar
• KappelhoffBSvan LethFRobinsonPAAre adverse events of nevirapine and efavirenz related to plasma concentrations?Antivir Ther2005104899816038474
   PubMed Web of Science ®Google Scholar
• KarrasALafaurieMFurcoATenofovir-related nephrotoxicity in human immunodeficiency virus infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidusClin Inf Dis20033610703
   PubMed Web of Science ®Google Scholar
• LambaVLambaJYasudaKHepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR expressionJ Pharmacol Exper Ther20033079062214551287
   PubMed Web of Science ®Google Scholar
• LevyJAPathogenesis of human immunodeficiency virus infectionMicrobiol Rev1993571832898464405
   PubMedGoogle Scholar
• LevyJAHIV and the Pathogenesis of AIDS20073Washington, D.CASM Press
   Google Scholar
• LittleSJSmithDMHIV treatment decisions and transmitted drug resistanceClin Infect Dis200541233515983921
   PubMed Web of Science ®Google Scholar
• Lyseng-WilliamsonKAReynoldsNAPloskerGLTenofovir disoproxil fumarate: a review of its use in the management of HIV infectionDrugs2005654133215669881
   PubMed Web of Science ®Google Scholar
• McCollDJMargotNAChuangSStudy 934: lower rates of resistance development associated with tenofovir DF and emtricitabine plus efavirenz by week 968th International Congress on Drug Therapy in HIV InfectionNovember 12–16, 2006Glascow, UK199
   Google Scholar
• McDonaldHPGargAXHaynesRBInterventions to enhance patient adherence to medication prescriptions: scientific reviewJ Amer Med Assoc2002288286879
   PubMed Web of Science ®Google Scholar
• MaglioneMGoetzMWangZAntiretroviral (ARV) Drug Resistance in the Developing WorldEvid Rep Technol Assess2007156174
   Google Scholar
• MarkowitzMNguyenB-YGotuzzoFPotent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naive HIV-1 infected patients2006Program and abstracts of the XVI International AIDS ConferenceAugust 13–18, 2006Toronto, Canada Abstract THLB0214
   Google Scholar
• MathiasAAHinkleJMenningMBioequivalence of efavirenz/emtricitabine/tenofovir DF single tablet regimenJ Acquir Immune Defic Syndr2007461677317667331
   PubMed Web of Science ®Google Scholar
• MontforeASabinCAPhillipsAThe changing incidence of AIDS events in patients receiving highly active antiretroviral therapyArch Intern Med20051654162315738371
   PubMedGoogle Scholar
• MotsingerAARitchieMDShaferRWMultilocus genetic interactions and response to efavirenz-containing regimens: an adult clinical trials group studyPharmacogenet Genomics2006168374517047492
   PubMed Web of Science ®Google Scholar
• MoyleGJDeJesusECahnPAbacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naïve HIV-infected adultsJ Acquir Immune Def Syndr20053841725
   PubMed Web of Science ®Google Scholar
• MurriRAmmasariATrottaMPPatient reported and physician estimated adherence to HAARTJ Gen Intern Med20041911041015566439
   PubMed Web of Science ®Google Scholar
• NabelGBaltimoreDAn inducible transcription factor activates expression of human immunodeficiency virus in T cellsNature198732671133031512
   PubMed Web of Science ®Google Scholar
• PalellaFJDelaneyKMMoormanACDeclining morbidity and mortality among patients with advanced human immunodeficiency virus infectionN Eng J Med199833885360
   PubMed Web of Science ®Google Scholar
• PatersonDLSwindellsSMohrJAdherence to protease inhibitor therapy and outcomes in patients with HIV infectionAnn Intern Med2000133213010877736
   PubMed Web of Science ®Google Scholar
• PerelsonASNeumannAUMarkowitzMHIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation timeScience1996271158268599114
   PubMed Web of Science ®Google Scholar
• PeyriereHReynesJRouanetIRenal tubular dysfunction associated with tenofovir therapy: report of 7 casesJ Acquir Immune Defic Syndr2004352697315076241
   PubMed Web of Science ®Google Scholar
• PfisterMLabbeLHammerSMPopulation pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavirAntimicrob Agents Chemother200347130712499180
   PubMed Web of Science ®Google Scholar
• PozniakALGallantJEDeJesusETenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysisJ Acquir Immune Defic Syndr2006435354017057609
   PubMed Web of Science ®Google Scholar
• RahimSFredrickLMda SilvaBGeographical and temporal trends of transmitted HIV-1 resistance amount antiretroviral naïve subjects screening for clinical trials20072007 International HIV Drug Resistance WorkshopJune 12–16, 2007Barbados, West Indies Abstract #49
   Google Scholar
• RayASCihlarTRobinsonKLMechanism of active renal tubular efflux of tenofovirAntimicrob Agents Chemother2006329730417005808
   PubMed Web of Science ®Google Scholar
• RibaudoHJHaasDWTierneyCPharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an AIDS clinical trial group studyClin Infect Dis200642401716392089
   PubMed Web of Science ®Google Scholar
• RiddlerSAHaubrichRDiRienzoGA prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142Program and abstracts of the XVI International AIDS ConferenceAugust 13–18, 2006Toronto, Canada Abstract THLB0204
   Google Scholar
• RobbinsBLSrinivasRVKimCAnti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropylmoxymethylcarbonyl)PMPAAntimicrob Agent Chemother1998426127
   PubMed Web of Science ®Google Scholar
• RollotFNazalEChauvelot-MoachonLTenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with aquired immune deficiency syndrome: the role of lopinavir-ritonavir-didanosine200337e1746
   Google Scholar
• RossLLWilliamsVWineBChanges in the regional prevalence of HIV-1 drug resistance-associated mutations and in the prevalence of non-clade B sub types in antiretroviral therapy-naïve HIV-infected patients in the United States from 2000–200620072007 International HIV Drug Resistance WorkshopJune 12–16, 2007Barbados, West Indies Abstract #47
   Google Scholar
• RuedaSPark-WyllieLYBayoumiAMtient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDSCochrane Database of Systematic Reviews20072
   Web of Science ®Google Scholar
• SarkarIHauberIHauberJBuchholzFHIV-1 proviral DNA excision using an evolved recombinaseScience2007161912517600219
   PubMed Web of Science ®Google Scholar
• SambamoorthiUWalkupJOlfsonMAntidepressant treatment and health services utilization among HIV-infected symptoms Medicaid patients diagnosed with depressionJ Gen Intern Med2000153112010840266
   PubMed Web of Science ®Google Scholar
• SimenBBUltradeep versus standard sequencing in subset of FIRST trial participants2007 International HIV Drug Resistance WorkshopJune 12–16, 2007Barbados, West Indies Abstract 134
   Google Scholar
• StaszewskiSPozniakALGallantJRenal safety profile of tenofovir DF (TDF)-containing compared to non-TDF-containing regimens in antiretroviral naïve patients with mild renal impairment or hypertension and/or diabetes mellitus20068th International Congress on Drug Therapy in HIV InfectionNovember 12–14, 2006Glasgow, Scotland, UK Abstract P157
   Google Scholar
• Sustiva® Package InsertSustiva (efavirenz) capsules and tablets prescribing information [online]2007New JerseyBristol-MyersSquibb Company, Princeton January 2007. Accessed August 10, 2007. URL: http://www.bms.com
   Google Scholar
• TirelliUVaccherECarboneAHTLV-III infection among 315 intravenous drug abusers: seroepidemiological, clinical and pathological findingsAIDS Res19852325343814261
   PubMedGoogle Scholar
• Truvada® Package Insert2006Foster City, California, USGilead Sciences, Inc March 2006
   Google Scholar
• TurnerBJLaineCCoslerLRelationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug usersJ Gen Intern Med2003182485712709091
   PubMed Web of Science ®Google Scholar
• Van DulmenSSluijsEvan DijkLPatient adherence to medical treatment: A review of reviewsBMC Health Services Research200775517439645
   PubMed Web of Science ®Google Scholar
• VervoortSCBorleffsJMHoepelmanJCAdherence in antiretroviral therapy: A review of qualitative studiesAIDS2006212718117255734
   PubMed Web of Science ®Google Scholar
• Viread® Package Insert2007Foster City, CaliforniaGilead Sciences, Inc. May 2007
   Google Scholar
• WeiXGhoshSKTaylorMEViral dynamics in human immunodeficiency virus type-1 infectionNature1995373117227529365
   PubMed Web of Science ®Google Scholar
• WensingAMVercauterenJvan de VijverDATransmission of HIV drug resistance in Europe2006Program and abstracts of the XVI International AIDS ConferenceAugust 13–18, 2006Toronto, Canada Abstract TUAB0101
   Google Scholar
• YerlySvon WylVLedergerberBTransmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology surveyAIDS2007212223918090050
   PubMed Web of Science ®Google Scholar
• YoungSDBritcherSFTranLOL-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptaseAntimicrob Agents Chemother199539260258592986
   PubMed Web of Science ®Google Scholar
• YunLWMaraviMKobayashiJSAntidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patientsJ Acquir Immun Defic Syndr2005384328
   PubMed Web of Science ®Google Scholar